Founded in 1999, Prolacta Bioscience is the leading provider of 100% human milk-based neonatal nutritional products to hospital neonatal intensive care units (NICUs).
Location: United States
Employees: 201-500
Phone: +1 626-599-9260
Total raised: $56M
Founded date: 1999
Investors 7
| Date | Name | Website |
| - | Alta Partn... | altapartne... |
| - | Frontier V... | draperfron... |
| - | Aisling Ca... | aislingcap... |
| - | Mercury Fu... | mercuryfun... |
| - | Frontier O... | frontiervc... |
| - | EW Healthc... | ewhealthca... |
| - | PROOF Fund | proof.vc |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.05.2018 | - | $9M | - |
| 06.12.2016 | - | $35M | - |
| 23.05.2007 | - | $12M | - |
Mentions in press and media 19
| Date | Title | Description |
| 19.02.2026 | A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants | Japan's Ministry of Health, Labour and Welfare (MHLW) Approves PreemieFort® Enteral Solution as Prescription Medicine in the NICU DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ -- Prolacta Bioscience® today announced that Japan's Ministry of He... |
| 12.02.2026 | Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan | Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants present... |
| 13.05.2025 | Improved Survival and Growth While Cutting Malnutrition for Premature Infants Fed Human Milk-Based Fortifiers at Sydney Hospital | Study Demonstrates Multiple Benefits of Prolacta's Exclusive Human Milk Diet Compared to Traditional Cow Milk-Based Feeding Protocol ADELAIDE, Australia, May 13, 2025 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provid... |
| 10.12.2024 | Adoption of an Exclusive Human Milk Diet Reduces Malnutrition Rates Among Vulnerable Premature Infants in Sydney Hospital | Preliminary Data From Observational Study Presented at Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference ADELAIDE, Australia, Dec. 10, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospita... |
| 21.10.2024 | The Battle for Baby Nutrition: A New Dawn for Premature Infants in Australia | In the world of neonatal care, every ounce counts. For premature infants, the right nutrition can mean the difference between life and death. Recent developments in Australia highlight a significant shift in how these vulnerable babies are ... |
| 21.10.2024 | Humavant® 100% Human Milk-Based Fortifiers Helping Premature Infants in Australia Grow and Develop | Human Milk-Based Nutrition Is Clinically Demonstrated to Improve Health Outcomes in Very Low Birth Weight Babies Compared to Cow Milk-Based Products ADELAIDE, Australia, Oct. 21, 2024 /PRNewswire/ -- Prolacta Bioscience®, the world's leadin... |
| 10.11.2020 | Prolacta Bioscience Fortifiers Reduce Risk of Serious Lung Disease and Hospital Costs Among Premature Infants, Compared to Cow Milk-Based Fortifiers | |
| 04.11.2020 | Pushing for US & Middle East to eat organic, Saudi prince joins Back To The Roots round | KBW Ventures, the early-stage investment firm run by Saudi Arabian prince Khaled bin Alwaleed bin Talal Al Saud, has joined an investment round into Oakland, California’s organic gardening company Back to the Roots. The round, of undisclose... |
| 20.01.2020 | Why is a vegan Saudi prince investing in breast milk made from stem cells? | TurtleTree Labs, a Singapore-based biotech startup that has invited AFN to taste a glass of its lab-grown mother’s milk this spring, has completed its pre-seed funding round. Alternative protein investors Lever VC led the round. They were j... |
| 15.05.2018 | Prolacta Bioscience Raises $9 Million | - |
Show more